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Introduction
Canakinumab (CAN), a selective, human, anti-
interleukin-1b monoclonal antibody, has been shown
to be efficacious in the treatment of SJIA (Ruperto et
al. N Engl J Med 2012).
Objectives
To explore baseline demographics and clinical charac-
teristics that are most predictive of response to CAN in
CAN-naïve SJIA patients during the initial 12 weeks of
therapy.
Methods
Data from 3 trials were pooled for this analysis. CAN-
naïve patients (pts; n=178) aged 2–19 years with active
SJIA were enrolled and received sc CAN 4 mg/kg/month;
Predictors of response (according to aACR* 30, 70, and
Inactive Disease [ID]) at Days (D) 15, 29, 57 and 85 were
explored using univariate and multivariate logistic regres-
sion analyses. The candidate predictors (categorical vari-
ables) of CAN-response considered were: Age group,
Gender, Prior NSAIDS (no/yes), Prior MTX(no/yes),
Steroids (0, >0 – ≤0.4;> 0.4), Number of Active Joints
(≤10, 11-≤20, >20) and Joints with Limitation of Motion
(≤10, 11-≤20,>20), CRP (elevated/normal) at baseline and
at D15. All candidate predictors with p<0.1 in univariate
analyses were included in the multivariate analysis. *ACR
response plus absence of fever.
Results
By week 2 there was substantial clinical benefit with
102 pts (57%) and 36 pts (20%) achieving aACR70 and
ID, respectively; by week 12, 108 pts (61%) had aACR70
and 50 pts (28%) ID. The multivariate analysis indicated
that normal CRP at D15 is the only predictor significant
(all p < 0.05) for ID at all time-points (Table 1).
Conclusion
This exploratory analysis suggests that CAN-naïve
patients with normal CRP (i.e. ≤10 mg/l) at Day 15,
lower baseline steroid doses, low number of active
joints, no prior anti-TNF or prior NSAID use are those
most likely to achieve inactive disease up to 12 weeks.
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Table Inactive Disease - Multivariate logistic regression analysis on 12-week data
Variable*, Odds Ratio (95% CI) Day 15 Day 29 Day 57 Day 85
CRP at Day 15 (elevated vs normal) 0.20 (0.07, 0.55) 0.14 (0.04, 0.41) 0.26 (0.10, 0.66) 0.31 (0.12, 0.82)
Number of active joints (11-≤20 vs. ≤10) 0.22 (0.03, 1.66) 0.55 (0.09, 3.41) 0.17 (0.031, 0.97) 0.37 (0.06, 2.10)
Number of active joints (≤10 vs. >20) 2.56 (0.12, 55.39) 1.53 (0.06, 37.44) 16.10 (1.00, 258.12) 25.41 (1.60, 404.61)
Prior NSAID treatment (no vs. yes) 2.01 (0.71, 5.71) 9.33 (2.44, 35.68) 3.10 (1.03, 9.31) 5.31 (1.66, 17.05)
Steroid Level (0 vs. >0.4 mg/kg/day) 5.48 (0.97, 31.01) 8.89 (1.26, 62.64) 2.98 (0.51, 17.46) 11.16 (1.72, 72.34)
Steroid Level (>0.4 vs. >0-≤0.4 mg/kg/day) 0.32 (0.08, 1.29) 0.41 (0.09, 1.82) 0.81 (0.25, 2.60) 0.13 (0.03, 0.57)
Prior MTX treatment (no vs. yes) 1.94 (0.75, 5.00) 2.78 (0.93, 8.33) 2.79 (1.04, 7.51) 1.77 (0.65, 4.83)
Prior anti-TNFs treatment (no vs. yes) 1.83 (0.52, 6.49) 3.62 (0.77, 17.00) 2.01 (0.63, 6.38) 3.64 (1.04, 12.77)
Values in bold are significant; *Significant in at least one time point
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